Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints – Reuters

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com